A Phase I/II Study of Palbociclib, Letrozole and T-DM1 in Trastuzumab Refractory Estrogen Receptor Positive (ER+) and HER2 Positive Metastatic Breast Cancer
Phase of Trial: Phase I/II
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Letrozole (Primary) ; Palbociclib (Primary) ; Trastuzumab emtansine (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 12 Nov 2019 Planned number of patients changed from 62 to 4.
- 12 Nov 2019 Status changed from active, no longer recruiting to recruiting.
- 08 Nov 2019 Status changed from not yet recruiting to active, no longer recruiting.